Citations

Showing 10 of 108081 citations.

Impact of Early Gastrojejunal Stenosis on Weight Loss in Patients Undergoing Roux-en-Y Gastric Bypass
Shariq, Omair A. , Portela, Ray , Bews, Katherine A. , Kellogg, Todd A., Dayyeh, Barham Abu, Kendrick, Michael L. , Ghanem, Omar M. , Mundi, Manpreet S. , Kellogg, Todd A., Habermann, Elizabeth B.

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | March 27, 2023 | Volume: 33 | Issue: 2 | Pages: 202-206

10.1097/sle.0000000000001165 | PMID 36971521 Get It

Background: Gastrojejunal (GJ) anastomotic stenosis is a well-described complication after Roux-en-Y gastric bypass (RYGB); however, its impact on weight loss outcomes is not well elucidated. Methods: We performed a retrospective cohort study of adult patients who underwent RYGB at our institution between 2008 and 2020. Propensity score matching was used to match 30 patients who developed GJ stenosis within the first 30 days post-RYGB with 120 control patients who did not develop this outcome. Short and long-term complications and mean percentage of total body weight loss (TWL) were recorded at 3 months, 6 months, 1 year, 2 years, 3 to 5 years, and 5 to 10 years postoperatively. Hierarchical linear regression modeling was used to analyze the association between early GJ stenosis and the mean percentage of TWL. Results: Patients who developed early GJ stenosis had a 13.6% increase in the mean percentage of TWL when compared with controls in the hierarchical linear model [P < 0.001 (95% CI: 5.7; 21.5)]. These patients were also more likely to present to an intravenous infusion center (70% vs 4%; P < 0.01), require readmission within 30 days (16.7% vs 2.5%; P < 0.01), and/or develop an internal hernia (23.3% vs 5.0%) postoperatively. Conclusions: Patients who develop early GJ stenosis after RYGB have a greater degree of long-term weight loss compared with patients who do not develop this complication. Although our findings support the key contribution that restrictive mechanisms play in maintaining weight loss after RYGB, GJ stenosis remains a complication associated with significant morbidity.
Executive summary of the SAEM 2022 consensus conference to address racism in emergency medicine clinical research, training, and leadership
Chen, Esther H. , Dessie, Almaz , Druck, Jeffrey , Norman, Marquita S., Raukar, Neha P. , Raukar, Neha

Mayo Clinic

Academic Emergency Medicine | March 27, 2023 | Volume: 30 | Issue: 7 | Pages: 765-772

10.1111/acem.14727 | PMID 36971068 Get It

AbstractIntroductionRacism has not only contributed to disparities in health care outcomes, but also has negatively impacted the recruitment, retention, and promotion of historically excluded groups in academic medicine. The 2022 Society for Academic Emergency Medicine (SAEM) consensus conference, “Diversity, Equity, and Inclusion: Developing a Research Agenda for Addressing Racism in Emergency Medicine,” convened a diverse group of researchers, educators, administrative leaders, and health care providers to help address the impact of racism in three domains in academic emergency medicine: clinical research, education and training, and academic leadership. The main goals of the consensus process were to identify current knowledge gaps and create a research agenda within each domain using an iterative consensus‐building methodology.MethodsThe planning committee identified three fundamental domains to develop a research agenda and created workgroups who completed a literature search to identify gaps in knowledge. After a consensus building process, potential questions were presented at the in‐person consensus conference. Ninety SAEM members representing faculty and trainees participated in breakout groups in each domain to generate consensus recommendations for priority research.ResultsFor clinical research, three research gaps with six questions (n) were identified: remedies for bias and systematic racism (3), biases and heuristics in clinical care (2), and racism in study design (1). For education and training, three research gaps with seven questions were identified: curriculum and assessment (2), recruitment (1), and learning environment (4). For academic leadership, three research gaps with five questions were identified: understanding the current diversity, equity, and inclusion (DEI) landscape and culture (1), analyzing programs that improve DEI and identifying factors that lead to improved diversity (3), and quantifying the value of professional stewardship activities (1).ConclusionThis article reports the results of the consensus conference with the goal of influencing emergency care research, education, and policy and facilitating collaborations, grant funding, and publications in these domains.
Safety and Efficacy With Pulsed Field Ablation: Having the Cake and Eating It Too
Zyl, Martin van , Asirvatham, Samuel J. , van Zyl, Martin , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | March 27, 2023 | Volume: 16 | Issue: 4 | Pages: No page available

10.1161/circep.123.011955 | PMID 36970977 Get It

Involvement in Chemotherapy Decision Making among Patients with Stage II and III Colon Cancer
Austin, Jessica D. , Shelton, Elizabeth, Crookes, Danielle M. , Tehranifar, Parisa , Neugut, Alfred I. , Shelton, Rachel C. , Austin, Jessica D

Mayo Clinic

MDM Policy & Practice | March 27, 2023 | Volume: 8 | Issue: 1 | Pages: No page available

10.1177/23814683231163189 | PMID 37009635 Get It

Background. To explore preferred and actual involvement in chemotherapy decision making among stage II and III colon cancer (CC) patients by sociodemographic, interpersonal, and intrapersonal communication factors. Methods. Cross-sectional exploratory study collecting self-reported survey data from stage II and III CC patients from 2 cancer centers located in northern Manhattan. Results. Of 88 patients approached, 56 completed the survey. Only 19.3% reported shared involvement in their chemotherapy decisions. We observed significant differences in preferred involvement by gender, with women preferring more physician-controlled decisions. CC patients with higher levels of decisional self-efficacy significantly preferred shared decisions ( F = 4.4 [2], P = 0.02). Actual involvement in decisions differed by race (physician controlled 33% for White v. 67% for Other, P < 0.01), age (shared control 18% for ≤55 y, 55% for 55–64 y, and 27% for 65+ y, P = 0.04), and perception of choice (shared control 73% “yes” v. 27% “no,” P = 0.02). Actual or preferred involvement did not differ by stage. Significantly higher levels of medical mistrust (discrimination t = 2.8 [50], P = 0.01; lack of support t = 3.6 [49], P < 0.01), and lower levels of decisional self-efficacy ( t = 2.5 [49], P = 0.01) were reported among women. Discussion. Reports of shared involvement around chemotherapy decisions is limited among CC patients. Factors influencing preferred versus actual chemotherapy decision making are complex and may differ; hence, more research is needed to understand and address factors contributing to discordance between preferred and actual involvement in chemotherapy decision making for CC patients. Highlights Shared involvement around chemotherapy decisions remains limited for patients diagnosed with colon cancer. Sociodemographic (age, race, gender), interpersonal (medical mistrust), and intrapersonal (decisional self-efficacy, perception of choice) factors that influence preferred involvement in chemotherapy decision making may differ from those influencing actual involvement in chemotherapy decision making. Shared involvement in chemotherapy decisions may look different than currently conceptualized, notably when uncertainty around the benefits exists.
Early validity and reliability evidence for the American Board of Emergency Medicine Virtual Oral Examination
Chudnofsky, Carl R., Reisdorff, Earl J. , Joldersma, Kevin B., Ruff, Kathleen C., Goyal, Deepi G. , Gorgas, Diane L., Reisdorff, Earl J

Mayo Clinic

AEM Education and Training | March 27, 2023 | Volume: 7 | Issue: 2 | Pages: No page available

10.1002/aet2.10850 | PMID 36994316 Get It

AbstractBackgroundThe American Board of Emergency Medicine (ABEM) in‐person Oral Certification Examination (OCE) was halted abruptly in 2020 due to the COVID‐19 pandemic. The OCE was reconfigured to be administered in a virtual environment starting in December 2020.ObjectivesThe purpose of this investigation was to determine whether there was sufficient validity and reliability evidence to support the continued use of the ABEM virtual Oral Examination (VOE) for certification decisions.MethodsThis retrospective, descriptive study used multiple data sources to provide validity evidence and reliability data. Validity evidence focused on test content, response processes, internal structure (e.g., internal consistency and item response theory), and the consequences of testing. A multifaceted Rasch reliability coefficient was used to measure reliability. Study data were from two 2019 in‐person OCEs and the first four VOE administrations.ResultsThere were 2279 physicians who took the 2019 in‐person OCE examination and 2153 physicians who took the VOE during the study period. Among the OCE group, 92.0% agreed or strongly agreed that the cases on the examination were cases that an emergency physician should be expected to see; 91.1% of the VOE group agreed or strongly agreed. A similar pattern of responses given to a question about whether the cases on the examination were cases that they had seen. Additional evidence of validity was obtained by the use of the EM Model, the process for case development, the use of think‐aloud protocols, and similar test performance patterns (e.g., pass rates). For reliability, the Rasch reliability coefficients for the OCE and the VOE during the study period were all >0.90.ConclusionsThere was substantial validity evidence and reliability to support ongoing use of the ABEM VOE to make confident and defensible certification decisions.
Isolated Peptide from Spider Venom Modulates Dendritic Cells In Vitro: A Possible Application in Oncoimmunotherapy for Glioblastoma
Mato, Felipe Cezar de, Barreto, Natália , Cordeiro, Gabriel , Munhoz, Jaqueline , Bonfanti, Amanda Pires , Sutti, Rafael , Cruz, Priscilla B. M., Sanches, Lívia Rentas , Bombeiro, André Luís , Chalbatani, Ghanbar Mahmoodi , Verinaud, Liana , Sutti, Rafael , Bombeiro, André Luis , Chalbatani, Ghanbar Mahmoodi , Mato, Felipe Cézar Pinheiro de, Silva, Thomaz Augusto Alves da Rocha e , Rapôso, Catarina

Mayo Clinic

Cells | March 27, 2023 | Volume: 12 | Issue: 7 | Pages: 1023

10.3390/cells12071023 | PMID 37048096 Get It

Dendritic cells (DCs) vaccine is a potential tool for oncoimmunotherapy. However, it is known that this therapeutic strategy has failed in solid tumors, making the development of immunoadjuvants highly relevant. Recently, we demonstrated that Phoneutria nigriventer spider venom (PnV) components are cytotoxic to glioblastoma (GB) and activate macrophages for an antitumor profile. However, the effects of these molecules on the adaptive immune response have not yet been evaluated. This work aimed to test PnV and its purified fractions in DCs in vitro. For this purpose, bone marrow precursors were collected from male C57BL6 mice, differentiated into DCs and treated with venom or PnV-isolated fractions (F1—molecules < 3 kDa, F2—3 to 10 kDa and F3—>10 kDa), with or without costimulation with human GB lysate. The results showed that mainly F1 was able to activate DCs, increasing the activation-dependent surface marker (CD86) and cytokine release (IL-1β, TNF-α), in addition to inducing a typical morphology of mature DCs. From the F1 purification, a molecule named LW9 was the most effective, and mass spectrometry showed it to be a peptide. The present findings suggest that this molecule could be an immunoadjuvant with possible application in DC vaccines for the treatment of GB.
Infantile perianal pyramidal protrusion: A retrospective review of 27 patients
Dhami, Ramneek K. , Isaq, Nasro A., Tollefson, Megha M.

Mayo Clinic

Pediatric Dermatology | March 27, 2023 | Volume: 40 | Issue: 3 | Pages: 468-471

10.1111/pde.15307 | PMID 36967585 Get It

AbstractBackgroundInfantile perianal pyramidal protrusion (IPPP) is a rare benign skin condition that is typically seen in infant girls. This condition is often mistaken for other skin lesions such as acrochordons, condyloma acuminatum, and sequelae of sexual abuse. Many clinicians are unfamiliar with IPPP which can lead to aggressive workup and treatment. The purpose of this study was to elucidate demographic data, clinical features, diagnostic workup, and management of IPPP in a large cohort of patients seen at an academic medical center.MethodsA retrospective review of patients diagnosed with IPPP at Mayo Clinic, Rochester, MN was conducted. Demographic data, examination findings, diagnostic workup, and treatments were noted.ResultsTwenty‐seven patients with IPPP, 24 of which were girls and 3 were boys from the ages of 1 day to 4 years (mean 10.8 months, median 8.6 months) were identified. Symptoms were reported in 63% (17/27) of patients. Four patients received treatment with topical corticosteroid or local anesthetic. No patient underwent skin biopsy.ConclusionIPPP is commonly observed in healthy prepubertal girls. Constipation is a common symptom. Awareness of this entity may prevent overtreatment and unnecessary evaluation.
Threshold-Responsive Colorimetric Sensing System for the Continuous Monitoring of Gases
Mo, Manni , Fu, Bo , Hota, Piyush , Cay-Durgun, Pinar , Cheng, Edward H., Wiktor, Peter , Tsow, Francis , Thomas, Leslie F., Lind, Mary Laura , Forzani, Erica , Thomas, Leslie, Wang, Ran

Mayo Clinic

Sensors | March 27, 2023 | Volume: 23 | Issue: 7 | Pages: 3496

10.3390/s23073496 | PMID 37050555 Get It

Colorimetric sensors are widely used because of their inherent advantages including accuracy, rapid response, ease-of-use, and low costs; however, they usually lack reusability, which precludes the continuous use of a single sensor. We have developed a threshold-responsive colorimetric system that enables repeated analyte measurements by a single colorimetric sensor. The threshold responsive algorithm automatically adjusts the sensor exposure time to the analyte and measurement frequency according to the sensor response. The system registers the colorimetric sensor signal change rate, prevents the colorimetric sensor from reaching saturation, and allows the sensor to fully regenerate before the next measurement is started. The system also addresses issues common to colorimetric sensors, including the response time and range of detection. We demonstrate the benefits and feasibility of this novel system, using colorimetric sensors for ammonia and carbon dioxide gases for continuous monitoring of up to (at least) 60 detection cycles without signs of analytical performance degradation of the sensors.
Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time
Power, Erica A. , Rechberger, Julian S. , Zhang, Liang , Oh, Ju‐Hee , Anderson, Jacob B. , Ge, Jizhi, Hinchcliffe, Edward H. , Elmquist, William F. , Nesvick, Cody L. , Power, Erica A , Rechberger, Julian S , Anderson, Jacob B , Daniels, David J.

Mayo Clinic

Neuro-Oncology Advances | March 27, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad033 | PMID 37128506 Get It

Abstract Background H3K27-altered diffuse midline glioma (DMG) is the deadliest pediatric brain tumor; despite intensive research efforts, every clinical trial to date has failed. Is this because we are choosing the wrong drugs? Or are drug delivery and other pharmacokinetic variables at play? We hypothesize that the answer is likely a combination, where optimization may result in a much needed novel therapeutic approach. Methods We used in vitro drug screening, patient samples, and shRNA knockdown models to identify an upregulated target in DMG. A single small molecule protein kinase inhibitor with translational potential was selected for systemic and direct, loco-regional delivery to patient-derived xenografts (PDX) and genetically engineered mouse models (GEMM). Pharmacokinetic studies were conducted in non-tumor bearing rats. Results Aurora kinase (AK) inhibitors demonstrated strong antitumor effects in DMG drug screens. Additional in vitro studies corroborated the importance of AK to DMG survival. Systemic delivery of alisertib showed promise in subcutaneous PDX but not intracranial GEMM and PDX models. Repeated loco-regional drug administration into the tumor through convection-enhanced delivery (CED) was equally inefficacious, and pharmacokinetic studies revealed rapid clearance of alisertib from the brain. In an effort to increase the drug to tumor residence time, continuous CED over 7 days improved drug retention in the rodent brainstem and significantly extended survival in both orthotopic PDXs and GEMMs. Conclusions These studies provide evidence for increasing drug-tumor residence time of promising targeted therapies via extended CED as a valuable treatment strategy for DMG.
Prevention of the Vertical Transmission of HIV; A Recap of the Journey so Far
Cárdenas, María C. , Farnan, Sheila, Hamel, Benjamin , Plazas, Maria C. Mejia , Sintim-Aboagye, Elise, Littlefield, Dawn, Punia, Sohan, Enninga, Elizabeth Ann L. , Temesgen, Zelalem , Theiler, Regan N. , Gray, Clive M. , Chakraborty, Rana , Cardenas, Maria Camila, Mejia Plazas, Maria Camila, Littlefield, Dawn R, Behl, Supriya, Enninga, Elizabeth Ann L , Theiler, Regan , Gray, Clive M , Chakraborty, Rana , Behl, Supriya , Johnson, Erica L.

Mayo Clinic

Viruses | March 27, 2023 | Volume: 15 | Issue: 4 | Pages: 849

10.3390/v15040849 | PMID 37112830 Get It

In 1989, one in four (25%) infants born to women living with HIV were infected; by the age of 2 years, there was 25% mortality among them due to HIV. These and other pieces of data prompted the development of interventions to offset vertical transmission, including the landmark Pediatric AIDS Clinical Trial Group Study (PACTG 076) in 1994. This study reported a 67.5% reduction in perinatal HIV transmission with prophylactic antenatal, intrapartum, and postnatal zidovudine. Numerous studies since then have provided compelling evidence to further optimize interventions, such that annual transmission rates of 0% are now reported by many health departments in the US and elimination has been validated in several countries around the world. Despite this success, the elimination of HIV’s vertical transmission on the global scale remains a work in progress, limited by socioeconomic factors such as the prohibitive cost of antiretrovirals. Here, we review some of the key trials underpinning the development of guidelines in the US as well as globally, and discuss the evidence through a historic lens.